Protagonist Therapeutics, Inc Cash and Cash Equivalents, Period Increase (Decrease)
Protagonist Therapeutics, Inc (PTGX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $17.03 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-03-07
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$74.94M.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $82.26M, a 517.86% increase year-over-year.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2015-12-31 was -$12.66M.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for the quarter ending 2015-09-30 was $13.31M.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for fiscal 2016 was $17.03M.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$5.27M, a 709.84% decline from fiscal 2014.
- Protagonist Therapeutics, Inc cash and cash equivalents, period increase (decrease) for fiscal 2014 was $864.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$74.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $7.32M derived: sum of 2 quarters · filed 2017-03-07 | $17.03M 10-K · filed 2017-03-07 | |
| 2016-09-30 | $82.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $91.97M 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | $9.71M 10-Q · filed 2016-09-15 | |||
| 2015-12-31 | -$12.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $656.00K derived: sum of 2 quarters · filed 2017-03-07 | -$5.27M 10-K · filed 2017-03-07 | |
| 2015-09-30 | $13.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $7.39M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$5.92M 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | $864.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |